Image de couverture de livre

Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Pegah Golabi, Soroor Owrangi, Zobair M. Younossi
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Soroor Owrangi, et autres
Publié: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
par: Sung Won Chung, et autres
Publié: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
par: Min Wu, et autres
Publié: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
par: Deepak Joshi, et autres
Publié: (2024)

Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
par: Rutao Lin, et autres
Publié: (2024)

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures
par: Raj Vuppalanchi, et autres
Publié: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
par: Pojsakorn Danpanichkul, et autres
Publié: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
par: Nabil Noureddin, et autres
Publié: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
par: Nobuharu Tamaki, et autres
Publié: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
par: Jannis Kountouras, et autres
Publié: (2024)

Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019
par: Pojsakorn Danpanichkul, et autres
Publié: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
par: Francisco Idalsoaga, et autres
Publié: (2024)

Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients
par: Anna Fettiplace, et autres
Publié: (2024)

Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms
par: Olafur S. Palsson, et autres
Publié: (2024)

Editorial: The future of managing drug induced liver injury
par: Amanda Nicoll
Publié: (2024)

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras
par: Daniel Tassone, et autres
Publié: (2024)

Review article: Oesophageal disorders in chronic liver disease
par: Francisco Idalsoaga, et autres
Publié: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
par: Yaomin Wang, et autres
Publié: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
par: Carolin V. Schneider, et autres
Publié: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
par: Zhuo Li, et autres
Publié: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
par: Lana Bridi, et autres
Publié: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
par: Parminder Kaur, et autres
Publié: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
par: Nobuharu Tamaki, et autres
Publié: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
par: Basile Njei, et autres
Publié: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
par: Richie Manikat, et autres
Publié: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
par: Ivan Arcari, et autres
Publié: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
par: Nina Dominik, et autres
Publié: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
par: Abdel‐Aziz Shaheen, et autres
Publié: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
par: Yewan Park, et autres
Publié: (2024)

Review article: The epidemiology and management of Clostridioides difficile infection—A clinical update
par: Lindsay M. Clarke, et autres
Publié: (2024)

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
par: Donghee Kim, et autres
Publié: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
par: Eunice X. X. Tan, et autres
Publié: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
par: Manya Prasad, et autres
Publié: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
par: Carolin V. Schneider, et autres
Publié: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
par: Mohamed I. Elsaid, et autres
Publié: (2024)

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
par: Victoria T. Kronsten, et autres
Publié: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
par: María Hernández‐Pérez, et autres
Publié: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
par: Samer Gawrieh, et autres
Publié: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
par: Richie Manikat, et autres
Publié: (2024)

Identification of four novel acute‐on‐chronic liver failure clusters with distinct clinical trajectories and mortality using machine learning methods
par: Nipun Verma, et autres
Publié: (2024)